Boehringer Ingelheim Pharmaceuticals recently presented results of the Phase III INPULSIS trials investigating the efficacy of OFEV ® (nintedanib) in patients with idiopathic pulmonary fibrosis (IPF) at the American College of Chest Physicians Annual Meeting (CHEST 2015).
The Phase III INPULSIS trials were randomized, double-blind studies designed to assess both the efficacy and safety of nintedanib (administered at 150 mg, twice a day) in patients with IPF when compared to patients treated with a placebo.
We are sorry that this post was not useful for you!
Let us improve this post!
Tell us how we can improve this post?